Skip to main content

Table 4 Associations between laboratory TLS and bortezomib-containing therapy in patients with multiple myeloma by sex (multivariate analysis)

From: Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study

  No. of patients with TLS/total No. (%) OR (95% CI) P-value
Female (n = 108)
 Therapy without bortezomib 2/42 (4.8) 1.00 (reference)  
 Bortezomib-containing therapy 3/66 (4.5) 0.77 (0.09–6.10) 0.804 a
Male (n = 102)
 Therapy without bortezomib 1/38 (2.6) 1.00 (reference)  
 Bortezomib-containing therapy 11/64 (17.2) 8.51 (1.04–69.60) 0.046 a
  1. TLS Tumor lysis syndrome, OR Odds ratio, CI Confidence interval
  2. a Multivariable adjusted for ISS stage 3, pretreatment serum creatinine level (> upper limit of normal range), and pretreatment serum uric acid level (> upper limit of normal range)
\